Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 7209872, 11 pages
Clinical Study

Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation

1Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, Mexico
2Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico
3Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, 06726 Mexico City, Mexico

Correspondence should be addressed to Galileo Escobedo; moc.nsm@godebocseg

Received 1 September 2017; Revised 7 December 2017; Accepted 18 December 2017; Published 21 February 2018

Academic Editor: Bernard Portha

Copyright © 2018 Camilo P. Martínez-Reyes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF-α), IL-10, proinflammatory (Mon-CD11c+CD206), and anti-inflammatory (Mon-CD11cCD206+) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls () and significantly increased values of TNF-α and Mon-CD11c+CD206, with concomitant reductions in IL-10 and Mon-CD11cCD206+. Increased IL-13 was extraordinarily well associated with hyperglycemia () and hypertriglyceridemia () but unexpectedly exhibited no significant correlations with TNF-α (), IL-10 (), Mon-CD11c+CD206 () or Mon-CD11cCD206+ (). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation.